pharmaphorum

DECEMBER 24, 2021

Biogen and Eisai head towards the end of the year with some much-needed good news in their Alzheimer’s programmes, as the FDA awards a fast-track designation to lecanemab, their follow-up to recently approved Aduhelm. The post Biogen, Eisai Alzheimer’s drug lecanemab fast tracked by FDA appeared first on.

Drugs 109

Drugs FDA Approval Trials Marketing 109

BioTech 365

JANUARY 25, 2022

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: New research on tau’s role in neurodegenerative diseases like Alzheimer’s could inform new treatments.New research on tau’s role in neurodegenerative diseases like Alzheimer’s could inform new treatments (..)

Research 40

Research 40

pharmaphorum

NOVEMBER 14, 2022

Roche’s Genentech division has reported disappointing top-line results from its highly-anticipated phase 3 trial of gantenerumab in early Alzheimer’s disease, in yet another setback for an amyloid-targeting drug. First the bad news.

Trials 52

Trials Drugs Antibody FDA Approval 52

BioTech 365

JUNE 21, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Roche’s Alzheimer’s antibody lowers biomarkers in inherited form of disease, though impact on symptoms is unclear.Roche’s Alzheimer’s antibody lowers biomarkers in inherited form of disease, though impact (..)

Antibody 40

Antibody Research 40

BioTech 365

SEPTEMBER 29, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: How exploiting a protective gene mutation might protect the brain from Alzheimer’s disease.How exploiting a protective gene mutation might protect the brain from Alzheimer’s disease aliu Wed, … Continue reading (..)

Gene 40

Gene Research 40

The Pharma Data

JANUARY 13, 2021

13, 2021 — A rare brain disease that causes loss of language skills doesn’t lead to memory loss, a new study finds. The condition is called primary progressive aphasia and about 40% of people who have it have underlying Alzheimer’s disease, according to researchers. WEDNESDAY, Jan. years later.

Medicine 52

Medicine Research 52

World of DTC Marketing

JULY 13, 2021

The FDA approves an Alzheimer’s drug with questionable data yet asks for more data from Pfizer on a COVID booster shot. It’s no coincidence that drug companies’ stock speculators bet on expanded approvals for either a buy or sell recommendation. We need to learn to say NO. Can we make sense of this?

Drugs 187

Drugs FDA Approval Medicine Trials 187

pharmaphorum

JUNE 7, 2021

Biogen and Eisai have defied the naysayers and secured an historic FDA approval for their amyloid-targeting antibody aducanumab as the first-ever disease-modifying treatment for Alzheimer’s disease. Breaking news: The FDA has approved Aducanumab, the first FDA-approved drug that delays decline due to Alzheimer’s.

FDA Approval 87

FDA Approval Drugs Trials Clinical Trials 87

World of DTC Marketing

SEPTEMBER 23, 2021

The suggestion by Pfizer’s CEO that drug pricing negotiations with the government would slow innovation is PR doubletalk. That is our horse s**t. The CEO of Pfizer claims the COVID-19 vaccine was developed in less than a year, but there are no vaccines against viruses and diseases that have existed for far longer.

Vaccination 214

Vaccination Vaccine Drugs Packaging 214

BioTech 365

DECEMBER 21, 2021

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Miscellaneous 22.12.2021 / 07:00 The issuer is solely responsible for the content of this announcement. Vivoryon Therapeutics Receives FDA Fast Track Designation for Varoglutamstat in Early Alzheimer’s Disease Halle (Saale) / Munich, … Continue reading →

40

40

The Pharma Data

JANUARY 12, 2021

12, 2021 — Drug maker Eli Lilly on Monday announced promising results from a small study of an experimental Alzheimer disease drug called donanemab. The two-year, phase 2 clinical trial included 272 patients with mild-to-moderate Alzheimer disease symptoms. the company’s chief scientific officer.

Drugs 52

Drugs Clinical Trials Clinical Trials Protein 52

BioTech 365

OCTOBER 17, 2021

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Study 18.10.2021 / 07:00 The issuer is solely responsible for the content of this announcement. Vivoryon Therapeutics Provides Update on Business and Progress of Varoglutamstat Clinical Development in Alzheimer’s Disease This announcement … Continue reading →

Clinical Development 40

Clinical Development Development 40

pharmaphorum

DECEMBER 22, 2021

The Japanese regulator looks like it could follow the European Commission and reject approval of Biogen and Eisai’s Alzheimer’s disease therapy Aduhelm, leaving the FDA an outlier in its stance on the drug. The post Japan looks set to follow EU in rejecting Alzheimer’s drug Aduhelm appeared first on.

Drugs 93

Drugs Marketing Trials Clinical Trials 93

pharmaphorum

JANUARY 5, 2023

With the FDA due to deliver a decision of Eisai and Biogen’s new Alzheimer’s disease candidate lecanemab tomorrow, the safety of the drug has been thrust into the spotlight by a case report detailing a fatality in one of their clinical trials.

Trials 52

Trials Medicine Clinical Trials Clinical Trials 52

STAT News

NOVEMBER 28, 2022

… A 65-year-old woman who was receiving a promising experimental treatment to slow the cognitive decline caused by her early Alzheimer’s disease recently died from a massive brain hemorrhage that some researchers link to the drug , Science reports. STAT reported on another such case last month.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Drugs 98

BioTech 365

MARCH 31, 2021

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Miscellaneous 01.04.2021 / 07:00 The issuer is solely responsible for the content of this announcement. Vivoryon Therapeutics to Host Virtual Event on Current Clinical Landscape in Alzheimer’s Disease Treatment Options with Leaders and … Continue reading →

40

40

The Pharma Data

JANUARY 25, 2021

“The establishment of an Advisory Board focusing on Alzheimer’s disease, and the recruitment of such an impressive group of scientific and clinical leaders in this field is an extremely important step forward for the Company,” stated Paul Brennan, NervGen’s President & CEO. Dr.

Clinical Development 40

Clinical Development Containment Development Research 40

The Pharma Data

JANUARY 15, 2021

Memory Preserved in Rare Aphasia Tied to Alzheimer Disease. 15, 2021 — Individuals with primary progressive aphasia (PPA) associated with Alzheimer disease (AD) have longitudinally preserved episodic memory, according to a study published online Jan. More News Resources. Professional. FRIDAY, Jan.

Medicine 52

Medicine Research 52

pharmaphorum

OCTOBER 27, 2021

Eli Lilly has followed through on its plan to file for approval of its Alzheimer’s disease candidate donanemab, and is planning to take on Biogen and Eisai with a head-to-head trial against their recently-approved Aduhelm drug. gingivalis detectable in their saliva at the start of the trial.

Trials 52

Trials Drugs Sales Bacteria 52

World of DTC Marketing

JUNE 5, 2021

There is disagreement whether obesity is really considered a disease or a behavioral risk factor, similar to smoking, alcohol, and substance abuse that may lead to disease. Obesity is a multifactorial disease in which environmental conditions and several genes play an important role in developing this disease.

Medicine 193

Medicine Gene Genetics Research 193

The Pharma Data

NOVEMBER 30, 2020

30, 2020 — The first blood test to help diagnose Alzheimer disease is now available in the United States, but some experts have a number of concerns about it. Louis is meant for people 60 years and older who have cognitive issues and are being assessed for Alzheimer disease. AP News Article. MONDAY, Nov.

FDA Approval 52

FDA Approval Doctors Doctor Sales 52

The Pharma Data

NOVEMBER 6, 2020

Multinutrient Intervention Slows Cognitive Decline in Alzheimer Disease. 6, 2020 — For individuals with prodromal Alzheimer disease, a multinutrient intervention can slow cognitive decline, according to a study recently published in Alzheimer’s & Dementia. More News Resources.

Production 40

Production Research Trials 40

Drug Discovery World

JULY 31, 2023

The news follows an announcement by the company last week that it would cut around 1,000 jobs, or 11% of its workforce, to allow investment into its product pipeline. In its second quarter results, the company said its new ‘Fit for Growth’ programme would generate approximately $1 billion in gross operating expense savings.

FDA Approval 52

FDA Approval Production Clinical Trials Clinical Trials 52

The Pharma Data

JANUARY 12, 2021

It appears that the gorillas were infected by an asymptomatic member of the park’s wildlife team who wore a mask while working, said the park’s executive director, Lisa Peterson. Experimental Alzheimer’s Drug Shows Promise. 6, the AP reported. . The effect was seen on brain scans. © 2021 HealthDay.

Clinical Trials 52

Clinical Trials Clinical Trials Drugs Protein 52

pharmaphorum

APRIL 8, 2022

The US Centres for Medicare and Medicaid Services (CMS) has firmed up its draft decision to limit reimbursement of Biogen’s Alzheimer’s disease therapy Aduhelm to a few thousand patients enrolled in clinical trials.

FDA Approval 48

FDA Approval Clinical Trials Clinical Trials Trials 48

pharmaphorum

JANUARY 12, 2022

Biogen’s difficult launch of controversial Alzheimer’s therapy Aduhelm has been made even harder by a proposal by Medicare to cover the drug only for certain patients enrolled in clinical trials. Lilly has already filed for approval of its candidate, and all three have late-stage trial data due to read out this year.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Drugs 52

Drug Discovery World

NOVEMBER 29, 2023

Researchers have created a mathematical model that can accurately depict Alzheimer’s disease progression in individual patients, paving the way for personalised treatment and faster development of therapies.

Development 52

Development Drugs Radiology Drug Trials 52

pharmaphorum

JULY 11, 2021

In another twist to the Aduhelm approval tale, FDA’s Janet Woodcock has called for an independent investigation into the relationship between agency staffers and Biogen executives. In the letter, she writes: “FDA’s decisions are far ranging and it is inevitable that some of those decisions will lead to controversy.”

Marketing 52

Marketing Trials Clinical Trials Clinical Trials 52

World of DTC Marketing

JUNE 23, 2021

Source: STAT News Our healthcare system can’t continue to support drugs that don’t have good clinical outcomes behind them. According to STAT News “Patrizia Cavazzoni, director of the FDA’s drug division, in an interview with STAT on Tuesday. “We I, therefore, find the FDA’s decision to be puzzling.

Drugs 218

Drugs FDA Approval Doctors Doctor 218

pharmaphorum

JUNE 9, 2021

The unexpected approval and lofty pricing of Biogen’s Alzheimer’s therapy Aduhelm is clearly the biopharma event of the year so far, but what are the broader implications for the industry as a whole? The drug is already approved to treat Parkinson’s disease psychosis.

Drugs 73

Drugs Gene Therapy Marketing Regulation 73

pharmaphorum

AUGUST 10, 2020

Biogen’s Alzheimer’s drug aducanumab could be on the market in the next few months after the FDA accepted a clinical trial dossier and granted a fast Priority Review. The FDA reserves these quick reviews for drugs that have the potential to improve care standards for serious diseases.

Drugs 102

Drugs Clinical Trials Clinical Trials Trials 102

pharmaphorum

MAY 17, 2021

Biogen has downbeat news about its gene therapy for the rare inherited eye disease, X-linked retinitis pigmentosa, announcing the shot failed to meet its target in a phase 2/3 study. The post Biogen’s eye disease gene therapy fails ahead of FDA Alzheimer’s ruling appeared first on.

Gene Therapy 42

Gene Therapy Gene Trials Development 42

pharmaphorum

DECEMBER 2, 2022

Following the news of two lecanemab-related deaths reported on the eve of the Clinical Trials on Alzheimer’s Disease (CTAD) 2022 conference, Eisai has now presented the full results from its phase 3 confirmatory Clarity AD study for early Alzheimer’s disease and published them in the New England Journal of Medicine (NEJM).

Trials 57

Trials Clinical Trials Clinical Trials Medicine 57

pharmaphorum

OCTOBER 18, 2021

Already struggling to make headway with its recently launched Alzheimer’s drug, Biogen suffered a major late-stage pipeline setback after its tofersen drug for amyotrophic lateral sclerosis (ALS) missed the mark in a late-stage study. 1/2) [link]. — MND Association (@mndassoc) October 17, 2021.

Trials 44

Trials Gene Editing Gene Gene Therapy 44

pharmaphorum

MAY 18, 2022

Considerable scientific progress across neurological diseases and disorders was reported at the recent 74th American Academy of Neurology (AAN) Annual Meeting. What may be important for healthcare professionals certainly makes encouraging news for patients waiting for effective solutions.

Gene Therapy 68

Gene Therapy Gene Genetics Development 68

pharmaphorum

FEBRUARY 1, 2021

The FDA has delayed its decision on aducanumab, the troubled Alzheimer’s drug from Biogen and Eisai by three months, raising hopes that it could be approved after all. Like all of these other drugs aducanumab looked to have failed to slow or stay disease progression.

Pharma Companies 70

Pharma Companies Drugs Regulation Development 70

pharmaphorum

JANUARY 13, 2023

These therapies have incredible potential to fight cancer and other diseases using the patient’s own immune system. And there are big questions about how these therapies will be paid for, particularly those that turn out to be essentially curative in a payment system that’s set up to treat cancer as a chronic disease.

Clinical Trials 96

Clinical Trials Clinical Trials Gene Therapy Trials 96